PSA vs XGN · rev $1.23B vs rev $37.2M
PSA (PSA) versus Exagen Inc (XGN) — a side-by-side from cached financials, not a winner call.
PSA (PSA) common stock.
Exagen Inc (XGN) is a diagnostics & research company listed on US.
Latest reported PSA revenue for 2026-06-30 was $1.23B. Net income was $500.0M. Revenue was up 1.2% from 2026-03-31 to 2026-06-30. PSA currently screens at market cap $0.
Latest reported XGN revenue for 2026-06-30 was $37.2M. Net income was -$7.2M. XGN currently screens at market cap $154.1M.
PSA currently screens at market cap $0. XGN currently screens at market cap $154.1M.
Not investment advice. Open the PSA and XGN stock pages for the full models.
Not investment advice.